IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK, Targeting an IND in 2024 To Enable First-In-Human Clinical Evaluation For Patients Having Tumors With MSI-High
Portfolio Pulse from Benzinga Newsdesk
IDEAYA Biosciences has announced a development candidate nomination of a Werner Helicase Inhibitor in collaboration with GSK. The company has earned a $3 million milestone from GSK and is eligible to receive up to $465 million in development milestones and $475 million in commercial milestones, along with 50% of U.S. net profits.
October 09, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK has entered into a collaboration with IDEAYA Biosciences, which could lead to the development of a new drug candidate.
The collaboration with IDEAYA Biosciences could potentially lead to the development of a new drug candidate, which could have a positive impact on GSK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
IDEAYA Biosciences has announced a significant collaboration with GSK, which could lead to substantial future revenues.
The collaboration with GSK and the potential for significant future revenues could have a positive impact on IDEAYA Biosciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100